Tracer library / [68Ga]Ga-BOT5035

[68Ga]Ga-BOT5035

Also written as [68Ga]Ga-BOT5035; [Ga-68]Ga-BOT5035

Radionuclide: Ga-68 t½ 67.71 min
Modality: PET
Production route: —
Stage: Clinical research
Syntheses indexed: 1

Fibrosis (non-oncologic)Dosimetry and biodistribution studies

What it is

Compound class: bicyclic peptide
Target / mechanism: Platelet derived growth factor receptor β (PDGFR-β) PMID 32805638
Clinical application: Liver fibrosis PMID 32805638
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Modular-Lab PharmTracer Eckert & Ziegler	—	—	43.7 ± 7.6% not corrected	97.7 ± 0.4%	BOT5035	32805638 2020 Nucl Med Biol synthesis platform (Modular-Lab PharmTrace, Eckert & Ziegler), disposable cassettes for 68Ga-labelling - The non-decay corrected radiochemical yield and radiochemical purity of the radiopharmaceutical were 43.7 ± 7.6% (n = 3, process validation)

Need this precursor?We can point you to suppliers for [68Ga]Ga-BOT5035, or handle the enquiry for you.

Get in touch

Quality control Preliminary - inferred from compound class

Ph. Eur. monograph: not verified No Ph. Eur. check is recorded for this entry.
USP monograph: not verified No USP check is recorded for this entry.

AppearancepHRCP HPLCHPLC UVRadionuclidic (HPGe)Half-lifeActivityEndotoxins (LAL)SterilityFilter integrityMolar activityMetal impuritiesGe-68 breakthrough

How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); radiometal tracer -> metal impurities (rule); Ga-68, generator production assumed (no synthesis data found) -> Ge-68 breakthrough (preliminary); receptor ligand with a saturable target -> molar activity (rule)

Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived

Setting up quality control?We can help you scope the equipment needed to release [68Ga]Ga-BOT5035.

Get in touch

Notes

Added from reverse module search (stage 6); 1 article(s) with Ga-68. | Stage 30 (2026-09-18): Stage was 'phase I'; normalised to 'Clinical research', original wording kept here.